Benzinga.com

FDA Approves Bristol Myers' Opdivo Plus Yervoy Combo For Untreated Colorectal Cancer Patients

The U.S. Food and Drug Administration (FDA) on Tuesday approved Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment of adult and pediatric ...
Healthline

All About Opdivo Qvantig

Opdivo Qvantig (nivolumab/hyaluronidase-nvhy) is a prescription drug used to treat certain types of cancer. Opdivo Qvantig comes as a liquid that’s injected under your skin. Opdivo Qvantig is used in ...
Nasdaq

Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) Compared to Opdivo Monotherapy...

Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) Compared to Opdivo Monotherapy in Patients with Microsatellite ...
Seeking Alpha

Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig™ with ENHANZE® for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo ...

Opdivo Qvantig demonstrated consistent efficacy and showed a comparable safety profile to IV Opdivo in the Phase 3 CheckMate-67T trial The subcutaneous administration of Opdivo Qvantig is faster, with ...
Seeking Alpha

Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications

Opdivo is the first and only PD-1 inhibitor approved for subcutaneous (SC) use in the European Union Approval is based on results from the Phase 3 CheckMate -67T clinical trial which demonstrated ...